Redifferentiation Therapy with Rosiglitazone in a case of Differentiated Thyroid Cancer with Pulmonary Metastases and Absence of Radioiodine Uptake;Experiencia con rosiglitazona como tratamiento rediferenciador en un caso de carcinoma papilar de tiroides con metástasis pulmonares y ausencia de captación de radioyodo

Revista Espanola de Medicina Nuclear

Volumn 30, Issue 4, 2011, Pages 241-243

  Elola, M ^a   Yoldi, A ^a   Emparanza, J I ^a   Matteucci, T ^a   Bilbao, I ^a   Goena, M ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

Radioiodine uptake; Redifferentiation; Rosiglitazone; Thyroid cancer

Indexed keywords

RADIOACTIVE IODINE; ROSIGLITAZONE; THYROGLOBULIN;

ARTICLE; BLOOD LEVEL; CASE REPORT; DIFFERENTIATED THYROID CANCER; HUMAN; LUNG METASTASIS;

EID: 79959264341     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/j.remngl.2010.08.001     Document Type: Article

References (10)

1. Schlumberger M.J., Filetti S., Hay J.D. Bocio difuso y nodular no tirotóxico y neoplasia de tiroides. Williams Tratado de Endocrinología 2009, 419-450. Elsevier, Madrid. 11a ed. H.M. Kronenberg, S. Melmed, K.S. Polonsky, P.R. Larsen (Eds.).
2. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009, 19:1167-1214.
3. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., Wiersinga W., et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006, 154:787-803.
4. Eustatia-Rutten C.F., Smit J.W., Romijn J.A., van der Kleij-Corssmit E.P., Pereira A.M., Stokkel M.P., et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta analysis. Clin Endocrinol (Oxf). 2004, 61:61-74.
5. Kebebew E., Lindsay S., Clark O.H., Woeber K.A., Hawkins R., Greenspan F.S. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid. 2009, 19:953-956.
6. Tepmongkol S., Keelawat S., Honsawek S., Ruangvejvorachai P. Rosiglitazone. Effect on Radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid. 2008, 18:697-704.
7. Kim W.G., Kim E.Y., Kim T.Y., Ryu J.S., Hong S.J., Kim W.B., et al. Redifferentiation Therapy with 13-cis Retinoic Acids in Radioiodine-Resistant thyroid cancer. Endocr J. 2009, 56:105-112.
8. Short S.C., Suovuori A., Cook G., Vivian G., Harmer C. A phase II study using retinoids as redifferentiation agents to increase iodine uptake en metastasic thyroid cancer. Short SC. Clin Oncol (R Coll Radiol). 2004, 16:569-574.
9. Liu Y.Y., Stokkel M.P., Pereira A.M., Corssmit E.P., Morreau H.A., Romijn J.A., et al. Bexarotene increases uptake of radioiodine in metastases of differentiated thyroid carcinoma. Eur J Endocrinol. 2006, 154:525-531.
10. Liu Y.Y., Stokkel M.P., Morreau H.A., Pereira A.M., Romijn J.A., Smit J.W. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2008, 68:605-609.